Every S-3 that Autonomix Medical Inc (AMIX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow AMIX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMIX filings page.
Autonomix Medical, Inc. (AMIX) is registering up to 1,071,826 shares of common stock for resale by a single selling stockholder, issuable upon exercise of Series E common stock purchase warrants at an exercise price of $6.25 per share.
Autonomix will not sell any shares in this offering and will receive cash only if the warrants are exercised, which, if fully exercised for cash, would generate up to about $6.7 million in gross proceeds, planned for working capital. As of August 31, 2026, 1,828,505 shares of common stock were outstanding. The company highlights that issuance of the warrant shares could materially dilute existing stockholders and that the volume of registered resale shares could pressure the trading price.
Autonomix recently effected a 1-for-21 reverse stock split, reducing outstanding common shares from 11,409,344 to 542,312 while keeping 500 million authorized shares unchanged. The independent auditor’s report on the March 31, 2026 financial statements includes an explanatory paragraph raising substantial doubt about the company’s ability to continue as a going concern.
Autonomix Medical, Inc. is registering up to 857,462 shares of common stock for resale by a single selling stockholder, issuable upon exercise of Series D warrants with a $5.75 exercise price. Autonomix is not selling any shares in this transaction and will receive cash only if the warrants are exercised for cash, which could total up to approximately $4.9 million in gross proceeds for working capital.
The warrants were issued in a July 2026 warrant inducement transaction tied to the exercise of Series C warrants that generated approximately $2.6 million in gross proceeds. As of July 27, 2026, 971,043 shares of common stock were outstanding, following a 1‑for‑21 reverse stock split that reduced shares outstanding from 11,409,344 to 542,349 while keeping 500 million authorized shares.
The company highlights that resale of a large block relative to shares outstanding could pressure the trading price and that full warrant exercise would materially dilute existing stockholders. Autonomix qualifies as an emerging growth company and its auditor has included a going concern explanatory paragraph in the latest annual financial statements.
Autonomix Medical, Inc. is registering 13,504,998 shares of common stock for resale by a selling stockholder, issuable upon exercise of outstanding warrants from a November 2025 PIPE transaction. The shares consist of 9,003,332 shares underlying Series C common stock purchase warrants and 4,501,666 shares underlying pre-funded warrants.
The company will not receive any proceeds from the resale, but could receive up to $7.7 million in gross proceeds if all Common Warrants are exercised in cash at $0.8607 per share. The PIPE itself generated approximately $5.0 million in gross proceeds. Autonomix is a development-stage medical device company developing a catheter-based system that both senses neural signals and applies radiofrequency ablation, initially targeting severe pain from pancreatic and other visceral cancers.
As of November 21, 2025, Autonomix had 6,907,678 shares of common stock outstanding, so full warrant exercise would significantly increase the share count. Beneficial ownership caps of 4.99% for Common Warrants and 9.99% for Pre-Funded Warrants limit how many shares the investor can hold at any one time.